← Back to Clinical Trials
Recruiting NCT06882850

Immunomodulation During Pregnancy

Trial Parameters

Condition Aspirin
Sponsor Unidade Local de Saúde de Coimbra, EPE
Study Type OBSERVATIONAL
Phase N/A
Enrollment 30
Sex FEMALE
Min Age 18 Years
Max Age N/A
Start Date 2024-02-01
Completion 2025-03-30

Brief Summary

The goal of this observational study is to learn about the effects of low dose aspirin in immunity Pregnant women taking aspirin for other reasons (preeclampsia prevention) will be studied. The main question it aims to answer is: evaluate the effect of LDA on the modulation of innate immunity cells (NK cells, monocytes, γδ T cells) and/or acquired immunity (B and T lymphocytes, Treg cells, Th cells). Participants already taking intervention A as part of their regular medical care for RA will answer online survey questions about their joint pain for 5 years.

Eligibility Criteria

Inclusion Criteria: - Singleton pregnancy * Patients attending prenatal consultations at the Obstetrics Service A of CHUC, with the first consultation occurring before 14 weeks of gestation * Gestational age determined by first-trimester ultrasound * Study group: Women classified as high risk for PE according to clinical/historical criteria and the Fetal Medicine Foundation algorithm. LDA-naïve. Exclusion Criteria: Multiple pregnancy * Autoimmune diseases * Prior use of LDA or other immunomodulatory medication before potential recruitment * History of spontaneous miscarriages and/or medical termination of pregnancy * Fetal malformation

Related Trials